Importer of Controlled Substances Application: Myonex Inc., 4337-4338 [2024-01134]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 15 / Tuesday, January 23, 2024 / Notices
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on November 17, 2023,
Invizyne Technologies, Inc., 750 Royal
Oaks Drive, Suite 106, Monrovia,
California 91016–6357, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
Controlled substance
Tetrahydrocannabinols ....
Drug
code
Schedule
I 7370 II
The company plans to bulk
manufacture the listed controlled
substance for the internal use
intermediates or for sale to its
customers. In reference to drug code
7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture this
drug as synthetic. No other activities for
this drug code is authorized for this
registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–01135 Filed 1–22–24; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on December 14, 2023,
Medi-Physics Inc. DBA GE Healthcare,
3350 North Ridge Avenue, Arlington
Heights, Illinois 60004–1412 applied to
be registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Drug Enforcement Administration
Controlled substance
[Docket No. DEA–1313]
Schedule
9041
9180
II
II
Importer of Controlled Substances
Application: Medi-Physics Inc. DBA GE
Healthcare
Cocaine ...........................
Ecgonine ..........................
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
The company plans to import
derivatives of the listed controlled
substances to be used for the
manufacture of a diagnostic product and
reference standards. No other activities
for these drug codes are authorized for
this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
AGENCY:
Medi-Physics Inc. DBA GE
Healthcare has applied to be registered
as an importer of basic class(es) of
controlled substance(s). Refer to
Supplementary Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before February 22, 2024. Such
persons may also file a written request
for a hearing on the application on or
before February 22, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Drug
code
VerDate Sep<11>2014
17:41 Jan 22, 2024
Jkt 262001
I
I
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–01133 Filed 1–22–24; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
4337
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 1314]
Importer of Controlled Substances
Application: Myonex Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Myonex Inc. has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to Supplementary Information
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before February 22, 2024. Such
persons may also file a written request
for a hearing on the application on or
before February 22, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on December 20, 2023,
Myonex Inc., 100 Progress Drive,
Horsham, Pennsylvania 19044, applied
to be registered as an importer of the
following basic class(es) of controlled
substance(s):
DATES:
E:\FR\FM\23JAN1.SGM
23JAN1
4338
Federal Register / Vol. 89, No. 15 / Tuesday, January 23, 2024 / Notices
Controlled substance
Amphetamine ..................
Lisdexamfetamine ...........
Methylphenidate ..............
Nabilone ..........................
Oxycodone ......................
Hydromorphone ...............
Hydrocodone ...................
Morphine ..........................
Oxymorphone ..................
Fentanyl ...........................
Drug
code
Schedule
1100
1205
1724
7379
9143
9150
9193
9300
9652
9801
II
II
II
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances in dosage
form for clinical trials, research, and
analytical purposes. No other activities
for these drug codes are authorized for
this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Claude Redd,
Acting Deputy Assistant Administrator.
Controlled substance
Marihuana Extract ...........
Marihuana ........................
Tetrahydrocannabinols ....
Drug
code
Schedule
7350
7360
7370
I
I
I
The company plans to bulk
manufacture the listed controlled
substances to supply the Drug
Enforcement Administration-registered
researchers for their approval studies.
No other activities for these drug codes
are authorized for this registration.
[FR Doc. 2024–01134 Filed 1–22–24; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Claude Redd,
Acting Deputy Assistant Administrator.
[Docket No. DEA–1312]
Bulk Manufacturer of Controlled
Substances Application: Maridose,
LLC
[FR Doc. 2024–01132 Filed 1–22–24; 8:45 am]
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
DEPARTMENT OF JUSTICE
BILLING CODE P
AGENCY:
Maridose, LLC has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to Supplementary
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 25, 2024. Such
persons may also file a written request
for a hearing on the application on or
before March 25, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on December 5, 2023,
Maridose, LLC, 74 Orion Street, Unit 7,
Brunswick, Maine 04011, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
VerDate Sep<11>2014
17:41 Jan 22, 2024
Jkt 262001
Notice of Lodging of Proposed Partial
Consent Decree Under the Clean Water
Act
On January 9, 2024, the Department of
Justice lodged a proposed Partial
Consent Decree with the United States
District Court for the District of Arizona,
in the lawsuit entitled United States v.
Navajo Tribal Utility Authority, Civil
Action No. 3:24–cv–08006.
The United States filed this lawsuit
under the Clean Water Act. The United
States’ complaint seeks injunctive relief
for violations of the limitations and
conditions established in the
defendant’s National Pollutant
Discharge Elimination System
(‘‘NPDES’’) permits at three of its
wastewater treatment facilities within
the Navajo Nation in Northeastern
Arizona. The Partial Consent Decree
requires the defendant to improve the
performance of its exiting treatment
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
plants in the short term, construct new
treatment plants over the longer term,
improve its operation and maintenance
of the facilities, and study its collection
systems to identify defects and plan for
their repair.
The publication of this notice opens
a period for public comment on the
Partial Consent Decree. Comments
should be addressed to the Assistant
Attorney General, Environment and
Natural Resources Division, and should
refer to United States v. Navajo Tribal
Utility Authority, D.J. Ref. No. 90–5–1–
1–12527. All comments must be
submitted no later than forty-five (45)
days after the publication date of this
notice. Comments may be submitted
either by email or by mail:
To submit
comments:
Send them to:
By email .......
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
During the public comment period,
the Partial Consent Decree may be
downloaded and examined from this
Justice Department website: https://
www.justice.gov/enrd/consent-decrees.
We will provide a paper copy of the
decree upon written request and
payment of reproduction costs. Please
mail your request and payment to:
Consent Decree Library, U.S. DOJ—
ENRD, P.O. Box 7611, Washington, DC
20044–7611.
Please enclose a check or money order
for $47.25 (25 cents per page
reproduction cost) payable to the United
States Treasury. For a paper copy
without the exhibits and signature
pages, the cost is $16.75.
Lori Jonas,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2024–01161 Filed 1–22–24; 8:45 am]
BILLING CODE 4410–15–P
LEGAL SERVICES CORPORATION
Notice of Availability of Calendar Year
2024 Competitive Grant Funds for the
Technology Initiative Grant Program
Legal Services Corporation.
Notice.
AGENCY:
ACTION:
The Legal Services
Corporation (LSC) issues this Notice
describing the conditions for submitting
a pre-application for 2024 Technology
Initiative Grants (TIGs), and for
SUMMARY:
E:\FR\FM\23JAN1.SGM
23JAN1
]]>Agencies
[Federal Register Volume 89, Number 15 (Tuesday, January 23, 2024)]
[Notices]
[Pages 4337-4338]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01134]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 1314]
Importer of Controlled Substances Application: Myonex Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Myonex Inc. has applied to be registered as an importer of
basic class(es) of controlled substance(s). Refer to Supplementary
Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
February 22, 2024. Such persons may also file a written request for a
hearing on the application on or before February 22, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on December 20, 2023, Myonex Inc., 100 Progress Drive,
Horsham, Pennsylvania 19044, applied to be registered as an importer of
the following basic class(es) of controlled substance(s):
[[Page 4338]]
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Amphetamine............................. 1100 II
Lisdexamfetamine........................ 1205 II
Methylphenidate......................... 1724 II
Nabilone................................ 7379 II
Oxycodone............................... 9143 II
Hydromorphone........................... 9150 II
Hydrocodone............................. 9193 II
Morphine................................ 9300 II
Oxymorphone............................. 9652 II
Fentanyl................................ 9801 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
dosage form for clinical trials, research, and analytical purposes. No
other activities for these drug codes are authorized for this
registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-01134 Filed 1-22-24; 8:45 am]
BILLING CODE 4410-09-P
